Anti-GD2-CAR engineered T cells Therapy

N/A

Report date: 2023/11/01 20:08:59

Base Information

Drug NameAnti-GD2-CAR engineered T cells Therapy
Drug Alias NameT Cells Expressing an Anti-GD2 Chimeric Antigen Receptor
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-GD2
TargetsDisialoganglioside GD2
Therapy Area/IndicationsMelanomaNeuroblastomaSarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsMelanomaNeuroblastomaSarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A